Shanghai Medicilon Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
2,504
- Stock Symbol
-
688202
- Investments
-
2
- Share Price
-
$9.42
- (As of Friday Closing)
Shanghai Medicilon General Information
Description
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
Contact Information
Website
www.medicilon.com.cnCorporate Office
- No. 585 Chuanda Road
- Pudong New Area
- Shanghai, 201299
- China
Corporate Office
- No. 585 Chuanda Road
- Pudong New Area
- Shanghai, 201299
- China
Shanghai Medicilon Stock Performance
As of 20-Nov-2026, Shanghai Medicilon’s stock price is $9.42. Its current market cap is $1.27B with 134M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.42 | $10.11 | $7.28 - $17.91 | $1.27B | 134M | 6.33M | -$0.05 |
Shanghai Medicilon Financials Summary
As of 30-Sep-2026, Shanghai Medicilon has a trailing 12-month revenue of $223M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,118,681 | 1,056,305 | 506,080 | 1,204,244 |
| Revenue | 222,709 | 161,731 | 144,624 | 193,025 |
| EBITDA | (6,165) | (9,669) | (37,551) | 6,849 |
| Net Income | (6,695) | (23,338) | (46,108) | (4,694) |
| Total Assets | 433,235 | 374,759 | 386,743 | 460,718 |
| Total Debt | 31,762 | 35,365 | 47,407 | 54,013 |
Shanghai Medicilon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shanghai Medicilon Comparisons
Industry
Financing
Details
Shanghai Medicilon Competitors (30)
One of Shanghai Medicilon’s 30 competitors is Aragen Life Sciences, a Private Equity-Backed company based in Hyderabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aragen Life Sciences | Private Equity-Backed | Hyderabad, India | ||||
| GenScript | Formerly VC-backed | Nanjing, China | ||||
| WuXi Biologics | Formerly VC-backed | Wuxi, China | ||||
| Personalis | Formerly VC-backed | Fremont, CA | ||||
| ChemPartner | Formerly PE-Backed | Shanghai, China |
Shanghai Medicilon Patents
Shanghai Medicilon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026184756-A1 | Crystal form of kif18a inhibitor drug, and preparation method therefor and use thereof | Pending | 07-Mar-2025 | ||
| WO-2026061544-A1 | Rnai formulation and use thereof | Pending | 23-Sep-2024 | ||
| WO-2023216707-A1 | Universal preclinical bio-distribution detection kit for nk cell therapy products | Inactive | 09-May-2022 | ||
| US-20250361559-A1 | Universal preclinical bio-distribution kit for nk cell therapy products | Pending | 09-May-2022 | ||
| US-20250177542-A1 | Preparation method for drug linker conjugate | Pending | 26-Jan-2022 | A61K47/64 |
Shanghai Medicilon Signals
Shanghai Medicilon Acquisitions (2)
Shanghai Medicilon’s most recent deal was a Merger/Acquisition with Meibang Qili. The deal was made on 12-Aug-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Meibang Qili | 12-Aug-2020 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Bestlinkage NHI | 05-Jul-2017 | Merger/Acquisition | Real Estate Services (B2C) |
Shanghai Medicilon ESG
Risk Overview
Risk Rating
Updated February, 29, 2024
19.51 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 70
Rank
Percentile
Shanghai Medicilon Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Meibang Qili | Shanghai, China | 2007 |
Shanghai Medicilon FAQs
-
When was Shanghai Medicilon founded?
Shanghai Medicilon was founded in 2004.
-
Where is Shanghai Medicilon headquartered?
Shanghai Medicilon is headquartered in Shanghai, China.
-
What is the size of Shanghai Medicilon?
Shanghai Medicilon has 2,504 total employees.
-
What industry is Shanghai Medicilon in?
Shanghai Medicilon’s primary industry is Drug Discovery.
-
Is Shanghai Medicilon a private or public company?
Shanghai Medicilon is a Public company.
-
What is Shanghai Medicilon’s stock symbol?
The ticker symbol for Shanghai Medicilon is 688202.
-
What is the current stock price of Shanghai Medicilon?
As of 20-Nov-2026 the stock price of Shanghai Medicilon is $9.42.
-
What is the current market cap of Shanghai Medicilon?
The current market capitalization of Shanghai Medicilon is $1.27B.
-
What is Shanghai Medicilon’s current revenue?
The trailing twelve month revenue for Shanghai Medicilon is $223M.
-
Who are Shanghai Medicilon’s competitors?
Aragen Life Sciences, GenScript, WuXi Biologics, Personalis, and ChemPartner are some of the 30 competitors of Shanghai Medicilon.
-
What is Shanghai Medicilon’s annual earnings per share (EPS)?
Shanghai Medicilon’s EPS for 12 months was -$0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process